In response to the view that MX1 is miles behind EMV: Peter...

In response to the view that MX1 is miles behind EMV:

Peter Rowland (CEO of MX1) was asked about EMV at an online forum. He is a very sober presenter, not given to hyberbole. As an engineer he is also very thorough and systematic and a major shareholder in MX1. He said that EMV is "not really a competitor" of MX1. He said the EMV product is an anomaly imager of the brain which is not the accepted clinical standard to diagnose a stroke. The size of the bleed has to be identified and measured precisely. Even before September 2021, MX1's product was very close to the clinical standard at a fraction of the weight and cost of existing traditional x-rays and the cadaver tests you mention are working toward exceeding the current performance of full blown 500 kg x-ray machines in trucks like the one used in Melbourne. All that said, ASA must see potential in both technologies otherwise they would not be funding both. I would like to hear from ASA on how they see the differences. But if Peter is right, the EMV product will need to change the clinical standard for diagnosing a bleed or clot stroke and this is an extra degree of difficulty that should be factored in.